Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levonorgestrel Intrauterine System Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 14, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

NCT03182140
View directory record Official record
Conditions
Contraception
Interventions
Kyleena
Drug
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
12
States / cities
Lakewood, Colorado • Sarasota, Florida • Wellington, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Postpartum Levonorgestrel-releasing Intrauterine System and Breastfeeding

NCT01555931
View directory record Official record
Conditions
Postpartum Contraception
Interventions
Levonorgestrel-releasing intrauterine system
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 24, 2014 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immediate Postpartum Insertion of Contraceptive Intrauterine Devices

NCT03657602
View directory record Official record
Conditions
Contraception
Interventions
Kyleena Intrauterine System, Mirena Intrauterine System
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 14, 2026, 5:54 AM EDT
Terminated Not applicable Interventional Results available

Immediate Postplacental IUD Insertion

NCT02169869
View directory record Official record
Conditions
Contraception
Interventions
Mirena, Paragard
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Sep 14, 2026, 5:54 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

NCT00995150
View directory record Official record
Conditions
Contraception
Interventions
LNG20, Mirena
Drug
Lead sponsor
Medicines360
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
1,910 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 14, 2026, 5:54 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

NCT01391052
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions
Norethindrone acetate pretreatment, No pretreatment
Drug · Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 14, 2026, 5:54 AM EDT
Withdrawn Not applicable Interventional

Levonorgestrel-Intrauterine System (LNG-IUS) Insertion in the Postpartum Period

NCT01088178
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)
Device
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
16 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 14, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stress Hormones and IUDs

NCT03499379
View directory record Official record
Conditions
Contraception, Mood Change
Interventions
Mirena, Paraguard
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

NCT03642210
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel 52 mg intrauterine system
Combination Product
Lead sponsor
Medicines360
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
29
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 14, 2026, 5:54 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

A Randomized, Controlled, Comparative Study of a Levonorgestrel Intrauterine System for the Prevention of Endometrial Cancer in Patients Aged 40-50 With BMI Greater Than 35

NCT00161226
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Levonorgestrel intrauterine system
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 14, 2026, 5:54 AM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Evaluation of the Efficacy, Safety, and Tolerability of LevoCept

NCT04457076
View directory record Official record
Conditions
Contraception, Women at Risk for Pregnancy
Interventions
LevoCept
Drug
Lead sponsor
Sebela Women's Health Inc.
Industry
Eligibility
Up to 45 Years · Female only
Enrollment
1,525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
27
States / cities
Berkeley, California • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Insertion of an Intrauterine Device (IUD) After Medical Abortion

NCT00621543
View directory record Official record
Conditions
Intrauterine Device Expulsion, Medical Abortion, Induced Abortion
Interventions
IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]
Device
Lead sponsor
Boston University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early vs. Interval Postpartum IUD Insertion

NCT03462758
View directory record Official record
Conditions
Contraception
Interventions
IUD
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 14, 2026, 5:54 AM EDT
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

NCT06904274
View directory record Official record
Conditions
Endometrial Hyperplasia
Interventions
BAY865028, Medroxyprogesterone acetate
Combination Product · Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • West Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

NCT01254292
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 29 Years · Female only
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
24
States / cities
Tucson, Arizona • La Mesa, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 14, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer

NCT02397083
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
Drug · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
18
States / cities
Greeley, Colorado • Loveland, Colorado • Honolulu, Hawaii + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 14, 2026, 5:54 AM EDT
Recruiting Phase 4 Interventional

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start

NCT05444582
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel 52 MG Intrauterine System
Drug
Lead sponsor
University of Utah
Other
Eligibility
16 Years to 35 Years · Female only
Enrollment
1,404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Maintaining Intrauterine Devices (IUDs) in Teens (MINT): A Randomization Trial

NCT00653159
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel-releasing intrauterine device (LNG-IUS), Copper T380A intrauterine device (CuT380A)
Device
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 18 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Acting Reversible Contraception

NCT01299116
View directory record Official record
Conditions
Contraception
Interventions
DMPA, oral contraceptives, Implanon®, ParaGard®, Mirena®
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
916 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 14, 2026, 5:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LNG-IUS at 2 Weeks Postpartum

NCT02121067
View directory record Official record
Conditions
Contraception, Malposition of Intrauterine Contraceptive Device
Interventions
Levonorgestrel Intrauterine System (LNG-IUS)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Sep 14, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

NCT00788671
View directory record Official record
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 14, 2026, 5:54 AM EDT